Evaluation of a modified FTA-ABS test

Multispot FTA-ABS

P. O'NEILL,¹ G. D. JOHNSON,² AND C. S. NICOL³

From the Department of Pathology,¹ Lambeth Hospital, Brook Drive, London, S.E.11, the M.R.C. Rheumatism Unit,² Canadian Red Cross Memorial Hospital, Taplow, Maidenhead, Berks., and the Venereal Diseases Department,³ St. Thomas's Hospital, London, S.E.1.

In this report we describe a modification of the Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) (Hunter, Deacon, and Meyer, 1964).

The work involved in processing immunofluorescent tests has probably discouraged the adoption of the FTA-ABS as a routine screening procedure. This difficulty will resolve when an automated immunofluorescent test becomes available. Meanwhile we have adapted to the FTA-ABS test a semi-automatic technique developed by us for processing immunofluorescence tests of all types (O'Neill and Johnson, 1970). The essential feature of the Multispot FTA-ABS technique is the testing of up to 22 sera on one standard microscope slide. Test areas are isolated one from another by a coating of water-repellent material.

Part I of this report describes the technique of the multispot FTA-ABS test. In part II we report results on 1,897 unselected sera screened by Reiter protein complement-fixation test (RPCFT), tests for reagin, and the multispot FTA-ABS test. Cases of unsuspected treponemal disease brought to light by the multispot FTA-ABS screen are described, and the use of the test for large-scale screening is discussed.

Part I Technique of the multispot FTA-ABS test

(1) PREPARATION OF COATED SLIDES

Precision glass microscope slides 0.8–1 mm. thick are alcohol washed. Using a syringe and 25 gauge needle, 12 or 22 small (1 mm.) drops of glycerin are deposited in two rows on each slide. Alternatively, a glycerin dispenser designed for this purpose may be used (O'Neill and Johnson, 1970). Slides are then *thoroughly* sprayed with an aerosol-dispensed preparation of a polymer of tetrafluoroethylene (PTFE) containing a bonding agent.* They are then rinsed under a running tap to remove glycerin, polished

dry, and stored. The areas protected by glycerin remain uncoated by Teflon and are the sites of the antigen spots. The PTFE coating between the slides is water-repellent and prevents the closely spaced serum drops from running together during the test. PTFE coating of slides has been described by Goldman (1968).

(2) PREPARATION OF ANTIGEN

Lyophilized Nichols strain *Treponema pallidum* (obtained from Baltimore Biological Laboratories) was reconstituted as directed with 1 ml. distilled water. Care was taken to mix the reconstituted reagent thoroughly, using a syringe and fine needle (25 gauge). Using the same syringe and needle, one drop of antigen suspension was deposited on each clear glass spot of a multispot PTFE-coated glass microscope slide. Each drop was then carefully sucked back into the syringe, and the remaining very thin film of antigen material was allowed to dry and then fixed by immersion of the slide in acetone for 10 minutes. In this way it was possible to prepare more than 1,000 antigen spots from 1 ml. lyophilized antigen. Reconstituted antigen may be left at 4°C. for 24 hours if it cannot all be used up in one day. Antigen slides are stored at –20°C. in dry airtight containers.

On several occasions during this trial fresh (non-lyophilized) Nichols strain *T. pallidum* (kindly supplied by Dr A. E. Wilkinson) was used as antigen. Spots were prepared and fixed as described above. The performance of treponemes from these two sources was identical and they both stored well, acetone fixed, at –20°C. When retested after 6 to 12 months' storage, organisms from both these sources gave correct titres with standard control sera.

We have tried out, but did not use in this trial, treponemes from other sources. Some of these were found unsatisfactory as antigen in that they gave low titres with control sera, did not store satisfactorily on slides at –20°C., or (in one case) reacted only very weakly with IgM antibody. We believe it is of the greatest importance that antigen should be thoroughly evaluated before use in the test. This point is also made by Király, Jobbágy, and Mecher (1965).

Fixation of antigen in 10 per cent. methanol is preferred by some workers (Tuffanelli, Wuepper, Bradford, and Wood, 1967; Roberts, Miller, and Binnings, 1968). We agree that methanol fixation gives a cleaner preparation, but our experience suggests that methanol-fixed smears store less well at –20°C. than acetone-fixed material.

Received for publication October 4, 1969.

A shortened version of this report was presented at the meeting of the M.S.S.V.D. in Budapest on June 16, 1969.

Correspondence to Dr. C. S. Nicol, Lydia Department, St. Thomas's Hospital, London, S.E.1.

*Fluoro Glide, Chemplast. Inc., N.J., obtainable from Marshall-Howlett Ltd., 44 Tower Hill, London, E.C.3.

scribed by us elsewhere (O'Neill and Johnson, 1970). Sera are sampled and diluted twelve at a time, and the dilutions deposited simultaneously, on a 12-spot coated slide, using a simple device operated by mouth suction. Specimens are taken in the clinic into 13 mm. external diameter disposable polystyrene tubes, and sampling takes place directly from these. Recently, tests on heparinized plasma have been carried out in parallel with tests on serum. Fifty samples compared in this way have given identical results on serum and plasma; however, plasma is preferable for ease of handling.

Using the semi-automatic technique, setting up time for 120 tests is approximately 45 minutes.

(7) READING RESULTS

Tests were read by blue light fluorescence, usually on a Reichart Zetopan microscope with HBO 200 light source. We found the best filter combination, with this light source, to be exciter filter 3G 12/2 mm. with barrier filter GG14, but several other combinations are suitable. With the iodine quartz light source we found Gillet and Siebert's 'Turner' interference filter, giving 85 per cent. transmission at 485 mm. very satisfactory.

Fluorescence was graded and reported as shown in Table I.

TABLE I *Reporting of Multispot FTA-ABS results*

Degree of fluorescence	Test reported as
Strong	Reactive
Moderate	Reactive
Weak	Weakly reactive
Very weak	Doubtful—repeat advised
Organisms vaguely visible	Non-reactive
Organisms invisible	Non-reactive

Part II Application of the multispot FTA-ABS test as a screening procedure

(1) PATIENTS STUDIED

These were consecutive unselected attenders at a venereal disease clinic on randomly chosen days:

(a) Patients coming for the first time, either on their own initiative, or referred by G.Ps, hospital departments, or contact tracers;

(b) Patients re-attending with previously diagnosed or suspected venereal disease.

Places of origin are represented in the following percentages: United Kingdom and Eire 64 per cent.; other European countries 6 per cent.; Jamaica 19 per cent.; other West Indies 3 per cent.; African countries 3 per cent.; other countries 5 per cent.

(2) TESTS PERFORMED

All attenders are given a Wassermann test (CWR) with Maltaner cardiolipin antigen, and a Reiter protein complement-fixation test. In addition selected patients have a quantitative Price's Precipitation Reaction (PPR) per-

formed. These are usually patients undergoing treatment for syphilis or new patients in whom syphilis is suspected.

The patients in this series all had in addition a multispot FTA-ABS test, as described above. This was performed on an aliquot of serum collected from the clinic laboratory before the results of routine serology were known, and taken to another hospital one mile distant where the test was carried out. The only information available at the time of the FTA-ABS testing was the laboratory serial number of each serum. The identity of patients and results of previous tests were not known. All FTA-ABS tests were performed and read by one observer.

(3) RESULTS

1,897 sera were tested. Tables II to VII compare the results obtained in the clinic laboratory using the RPCFT, CWR, and PPR with the results of the multispot FTA-ABS test: to simplify presentation, CWR and PPR results have been grouped together and are referred to jointly as tests for reagin. Tables VI and VII give details of 154 patients who were non-reactive in tests at the clinic, but reactive or doubtfully reactive in the multispot FTA-ABS test.

Multispot FTA-ABS compared with RPCFT (Table II)

Our experience using the multispot FTA-ABS test confirms earlier reports of the reduced sensitivity of the RPCFT when compared with fluorescent antibody techniques (Wilkinson and Rayner, 1966; Stevens, Boylan, and Memoli, 1967).

TABLE II *Multispot FTA-ABS results on 315 sera reactive or doubtfully reactive in the RPCFT. 161 of these sera were also reactive in tests for reagin*

Result in RPCFT	Total	Result in multispot FTA-ABS test		
		Reactive	Doubtful	Non-reactive
Reactive	225 (115)*	224	0	1
Doubtfully reactive	90 (46)*	76	6	8
Non-reactive	1582	133	70	1379

*Numbers in brackets indicate sera which were reactive also in tests for reagin

Of the 1,897 sera tested, 225 (11.8 per cent.) were reactive in the RPCFT, with or without additional reagin activity. All but one of these 225 were positive also in the multispot FTA-ABS test. The exception was a 19-year-old English girl in whom neither history nor clinical findings suggested a diagnosis of venereal disease, and in whom the treponemal immobilization test (TPI) was negative. Subsequently all serological tests became negative, and this incident was regarded as an acute biological false positive (BFP) reaction. Among 1,582 RPCFT negative sera were 133 giving

a positive multispot FTA-ABS test, and a further seventy giving a doubtful FTA-ABS test. These are discussed further when Tables IV to VI are considered.

FTA-ABS results on RPCFT negative, reagin positive sera (Table III)

39 sera found during clinic testing to react only in tests for reagin are shown in Table III. Details of the 33 patients concerned are shown in Table IV. Seventeen of them were positive in the FTA-ABS test, and in twelve of these a history of treponemal disease of long duration was available (15-41 years in the nine cases which could be precisely dated). Also of interest in Table IV are the four reagin-positive children of sera-positive mothers. In none of these was a positive FTA-ABS result obtained, though two were doubtfully reactive. Three of them, aged 2, 3, and 7 years, were thought clinically not to have congenital disease, and were not treated. The fourth child, aged 6 months, was clinically suspect and has since received treatment; after which the tests for reagin became negative.

TABLE IV Analysis of the 33 reagin-positive RPCFT-negative patients shown in Table III

Clinical diagnosis	Multispot FTA-ABS result		
	Reactive	Doubtful	Non-reactive
Late syphilis	9	0	0
Late congenital syphilis	1	0	0
Childhood yaws	2	0	0
Latent treponemal disease	4	0	0
Children of sero-positive mothers	0	2†	2‡
Acute BFP	0	0	1
Probable chronic BFP (TPI negative)	0	0	2
No information	1	0	9*

*Includes three antenatal patients

†Ages 7 yrs 6 mths

‡Ages 2 and 3 yrs

Multispot FTA-ABS results on sera negative in RPCFT and tests for reagin

Table V gives multispot FTA-ABS results on 1,537 sera found negative in all tests at the clinic laboratory.

TABLE V Multispot FTA-ABS results on 1,537 sera non-reactive in RPCFT and tests for reagin

FTA-ABS results	No. of tests	No. of patients
Reactive	112	86
Doubtfully reactive	68	62
Non-reactive	1,357	
Total	1,537	

The findings here are particularly relevant. Only 1,357 sera (88.3 per cent. of 1,537) were FTA-ABS negative; 112 (7.3 per cent.) were reactive in the multispot FTA-ABS test, and 68 (4.4 per cent. doubtfully reactive. Details of the 86 patients who contributed the 112 reactive sera are shown in Table VI. Although 46 of these patients were already known to the clinic as cases of treponemal disease, and a further three were under surveillance as contacts at the time of testing, FTA screening brought to our attention forty patients in whom treponemal disease was not suspected. In thirteen of these a diagnosis of syphilis (5 cases) or latent treponemal disease (8 cases) was subsequently confirmed. Of the remaining 27 cases, 24 were lost to follow-up as they defaulted or could not be re-contacted; they included fifteen West Indian and five African patients without definite history or stigmata of yaws. At the time of writing, follow-up is not yet complete on three female patients of United Kingdom origin who gave unexpected positive FTA-ABS results.

TABLE VI Clinical diagnosis in 86 patients reactive in the multispot FTA-ABS test, but non-reactive in RPCFT and tests for reagin

Diagnosis	No. of cases
Treated syphilis	33
Late latent treponemal disease	3
Neurosyphilis	1
Cardiovascular syphilis	1
Primary syphilis	5
Yaws	15
Follow-up inconclusive	24
Follow-up not yet completed	3
Infant of sero-positive mother	1
Total	86

TABLE III Multispot FTA-ABS results on 39 sera reactive or doubtfully reactive in tests for reagin, but non-reactive in RPCFT

Result in tests for reagin	No. of tests	No. of patients	Result in multispot FTA-ABS		
			Reactive	Doubtful	Non-reactive
Reactive	33	28	19	1	13
Doubtfully reactive	6	5	2	1	3
Total	39	33	21	2	16

- JOHNSON, G. D., BEUTNER, E. H., and HOLBOROW, E. J. (1967). *J. clin. Path.*, **20**, 720.
- JULIAN, A. J., LOGAN, L. C., and NORINS, L. C. (1969). *J. Immunol.*, **102**, 1250.
- KIRÁLY, K., JOBBÁGY, A., and MECHEK, T. (1965). *Bull. Wld. Hlth Org.*, **33**, 687.
- McKINNEY, R. M., SPILLANE, J. T., and PEARCE, G. W. (1964). *J. Immunol.*, **93**, 232.
- O'NEILL, P., and JOHNSON, G. D. (1970). *J. clin. Path.*, **23**, 185.
- ROBERTS, M. E., MILLER, J. N., and BINNINGS, G. F. (1968). *J. Bact.*, **96**, 1500.
- SARTORIS, S., STRANI, G. F., PIPPIONE, M., and LEIGHEB, G. (1968). *Minerva dermatol.*, **43**, 219.
- STEVENS, R. W., BOYLAN, J., and MEMOLI, A. J. (1967). *Amer. J. clin. Path.*, **47**, 408.
- TUFFANELLI, D. L., WUEPPER, K. D., BRADFORD, L. L., and WOOD, R. M. (1967). *New Engl. J. Med.*, **276**, 258.
- WILKINSON, A. E., and RAYNER, C. F. A. (1966). *Brit. J. vener. Dis.*, **42**, 8.

Évaluation d'une épreuve FTA-ABS modifiée Le 'Multispot' FTA-ABS

SOMMAIRE

L'épreuve FTA-ABS de Hunter, Deacon, et Meyer (1964) a été modifiée pour accélérer le processus de marquage et pour faciliter la lecture du résultat. En particulier, 10 ou 20 sérums plus 2 témoins, sont examinés sur chaque lame microscopique au lieu de 2 par lame dans les méthodes précédentes. Ceci permet à un opérateur de pratiquer en un jour 100 épreuves ou davantage.

1.897 épreuves de dépistage ont été effectuées jusqu'ici sur des sérums de consultants non choisis d'une clinique vénéréologique. Les résultats concordent avec des séries précédentes dans lesquelles le FTA-ABS avait été comparé aux autres tests sérologiques pour la syphilis. En outre, ce test ayant été utilisé pour le dépistage, il a été reconnu une affection tréponémique chez 13 malades chez lesquels il n'y avait aucun indice de ce diagnostic.